QIAGEN has received FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its U.S. syndromic testing portfolio for gastrointestinal infections. The panel rapidly detects five key bacterial pathogens—Campylobacter, Salmonella, STEC, Shigella, and Yersinia enterocolitica—in about one hour, supporting fast outpatient diagnostics. This is QIAGEN’s second FDA-cleared QIAstat-Dx panel in 2025 and complements their existing bacterial and viral GI panels, offering laboratories targeted, flexible solutions for diverse clinical settings.
Trending
- When GI Puts AI to Work Beyond Polyp Detection
- AI Model Detects Colorectal Cancer and Advanced Adenomas in Blood (Bioengineer)
- ACG: Anesthesia support, strategic integration of APPs needed to bolster GI workforce (Healio)
- Medicare adds specialty code for physician nutrition specialists (GI & Hepatology News)
- EnVision Endoscopy Announces Oversubscribed Series A Financing and Reaches First 50 Patient Procedures with SimpleStitch™ Suturing System (PR Newswire)
- GI centers can’t explain their cancellation spike (Becker’s GI & Endoscopy)
- Beyond Burnout: Recognizing and Reframing the Heartsink Response in Gastroenterologists and Hepatologists (Gastroenterology)
- AGA and AASLD Joint Guidelines on PBC Diagnosis and Management (Gastroenterology Advisor)
